Photo from wikipedia
DPP‐4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixed‐dose combinations – Qtern and Glyxambi – have now been approved for the treatment of… Click to show full abstract
DPP‐4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixed‐dose combinations – Qtern and Glyxambi – have now been approved for the treatment of type 2 diabetes. This article discusses their clinical trial efficacy, adverse effects and place in therapy.
Keywords:
inhibitor combined;
dpp sglt2;
sglt2 inhibitor;
combined therapy;
type diabetes;
type
Journal Title: Prescriber
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!